News NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2025-06-20 pm EDT			5-day change	1st Jan Change
16.69 ^USD	-0.65%		-4.90%	-43.99%

Jun. 04	Novocure Insider Sold Shares Worth $528,413, According to a Recent SEC Filing	MT
Jun. 02	NovoCure Limited - Special Call

Novocure Insider Sold Shares Worth $528,413, According to a Recent SEC Filing	Jun. 04	MT
NovoCure Limited - Special Call	Jun. 02
Zai Lab and Novocure Announce Results from the Phase 3 Panova-3 Trial of Tumor Treating Fields Therapy for Pancreatic Cancer to Be Presented At 2025 Asco Annual Meeting	May. 31	CI
Novocure Says Ttfields Therapy Shows Significant Improvement In Overall Survival For Pancreatic Cancer	May. 31	RE
Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting	May. 31	BU
Novocure Announces Results from the Phase 3 Panova-3 Trial of Novocure's Tumor Treating Fields Therapy for Pancreatic Cancer to Be Presented At 2025 ASCO Annual Meeting	May. 31	CI
Novocure Announces Upcoming Investor Events	May. 27	RE
Novocure Announces Upcoming Investor Events	May. 27	BU
NovoCure's Q1 Loss Narrows, Revenue Rises	Apr. 24	MT
NovoCure Limited, Q1 2025 Earnings Call, Apr 24, 2025	Apr. 24
Earnings Flash (NVCR) NOVOCURE Posts Q1 Revenue $155M, vs. FactSet Est of $146.9M	Apr. 24	MT
Earnings Flash (NVCR) NOVOCURE Posts Q1 Loss $-0.31 Per Share, vs. FactSet Est of $-0.46	Apr. 24	MT
NovoCure: Q1 Earnings Snapshot	Apr. 24	AQ
Novocure Reports First Quarter 2025 Financial Results	Apr. 24	BU
NovoCure Limited Reports Earnings Results for the First Quarter Ended March 31, 2025	Apr. 24	CI
Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting	Apr. 23	BU
Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of Its Tumor Treating Fields Therapy for Pancreatic Cancer as A Late-Breaking Oral Presentation At the 2025 ASCO Annual Meeting	Apr. 23	CI
Sector Update: Health Care Stocks Rise Late Afternoon	Apr. 22	MT
NovoCure Says Optune Lua Device Gets CE Mark to Treat Lung Cancer	Apr. 22	MT
Novocure'S Optune Lua® Receives CE Mark Approval	Apr. 22	RE
Novocure’s Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer	Apr. 22	BU
NovoCure : Corporate responsibility report (2025 novocure corp resp report 2025 04 19)	Apr. 21	PU
NovoCure : Proxy statement (e5332c8f 8bad 4662 8175 de4fabac5cb9)	Apr. 21	PU
Novocure to Report First Quarter 2025 Financial Results	Apr. 01	BU
Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference	Mar. 04	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Medical Equipment, Supplies & Distribution

Filters